Payment overview · 2025
General Payments
$316.21
17 reported records · 10 companies
Healthcare provider profile · identity verified
Christopher L Maynard, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATHENS, TN · NPI 1750386819
Verified facts
What the public records show
CMS Open Payments records show Christopher L Maynard, M.D. received $316.21 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Mounjaro, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.59 | 18.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.86 | 16.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.55 | 14.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.63 | 10.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.13 | 10.2% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.82 | 7.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.41 | 6.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.65 | 5.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.13 | 5.4% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $16.44 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.21 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.86 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 128 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
79 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
128 | 127 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 126 |
| Lisinopril | Lisinopril | 404 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 365 | 113 |
| Losartan Potassium | Losartan Potassium | 344 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 100 |
| Omeprazole | Omeprazole | 290 | 83 |
| Metformin Hcl | Metformin Hcl | 288 | 86 |
| Gabapentin | Gabapentin | 212 | 54 |
| Furosemide | Furosemide | 208 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 55 |
| Montelukast Sodium | Montelukast Sodium | 203 | 63 |
| Carvedilol | Carvedilol | 195 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 48 |
| Alprazolam | Alprazolam | 146 | 19 |
| Trazodone Hcl | Trazodone Hcl | 141 | 45 |
| Lorazepam | Lorazepam | 136 | 19 |
| Potassium Chloride | Potassium Chloride | 132 | 49 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 128 | 127 |
| Eliquis | Apixaban | 128 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 39 |
| Famotidine | Famotidine | 120 | 40 |
| Valsartan | Valsartan | 119 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 26 |
| Allopurinol | Allopurinol | 106 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 31 |
| Clonazepam | Clonazepam | 102 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 19 |
| Metformin Hcl Er | Metformin Hcl | 96 | 23 |
| Glimepiride | Glimepiride | 94 | 28 |
| Alendronate Sodium | Alendronate Sodium | 92 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 39 |
| Jardiance | Empagliflozin | 81 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 79 | 51 |
| Donepezil Hcl | Donepezil Hcl | 78 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 22 |
| Trulicity | Dulaglutide | 77 | 13 |
| Glipizide | Glipizide | 75 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 23 |
| Warfarin Sodium | Warfarin Sodium | 75 | 21 |
| Simvastatin | Simvastatin | 74 | 22 |
| Spironolactone | Spironolactone | 74 | 26 |
| Xarelto | Rivaroxaban | 74 | 17 |
| Ezetimibe | Ezetimibe | 70 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 23 |
| Estradiol | Estradiol | 61 | 20 |
| Sertraline Hcl | Sertraline Hcl | 60 | 24 |
| Benazepril Hcl | Benazepril Hcl | 59 | 16 |
| Meloxicam | Meloxicam | 59 | 34 |
| Celecoxib | Celecoxib | 58 | 19 |
| Tramadol Hcl | Tramadol Hcl | 58 | suppressed |
| Prednisone | Prednisone | 56 | 24 |
| Finasteride | Finasteride | 55 | 16 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 51 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 14 |
| Ozempic | Semaglutide | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 30 |
| Bumetanide | Bumetanide | 34 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 18 |
| Glyxambi | Empagliflozin/Linagliptin | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.21 · 17 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, ELIQUIS, FARXIGA, FFRct, FREESTYLE LIBRE 3, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, TZIELD, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error